nach oben

Erschienen in:

12.05.2023 | Case Report - Immunotherapy

Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis

verfasst von: Yusuke Seyama, Takeshi Yamada, Hirosumi Suzuki, Satoshi Fukuda, Miki Tsuji, Yusuke Niisato, Suguru Hirose, Yoshiyuki Yamamoto, Toshikazu Moriwaki, Ichinosuke Hyodo

Erschienen in: International Cancer Conference Journal | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Abstract

Gastric neuroendocrine carcinomas (NEC) are highly aggressive cancer with dismal prognosis. Platinum-based chemotherapy is used as the first-line treatment for this entity. However, there are no established therapeutic guidelines for platinum-resistant gastric NEC. We herein report a patient with metastatic gastric NEC who achieved durable and complete response to nivolumab with radiotherapy for oligoprogressive metastasis. A 70-year-old male patient had recurrences of resected gastric NEC, involving the liver and lymph nodes. His disease became refractory to cisplatin and etoposide combination therapy, after which he was treated with nivolumab. All the tumors showed marked shrinkage. However, 1 year after starting nivolumab, one metastatic lesion of the liver began to enlarge, and radiotherapy was performed to the lesion. Thereafter, a complete response was obtained, which has been maintained without any treatment for the past 2 years.

Das S, Dasari A (2021) Epidemiology, incidence, and prevalence of neuroendocrine neoplasms: are there global differences? Curr Oncol Rep 23:43. https://doi.org/10.1007/s11912-021-01029-7CrossRefPubMedPubMedCentral

Garcia-Carbonero R, Sorbye H, Baudin E et al (2016) ENETS consensus guidelines for high-grade gastroenteropancreatic neuroendocrine tumors and neuroendocrine carcinomas. Neuroendocrinology 103:186–194. https://doi.org/10.1159/000443172CrossRefPubMed

Kunz PL, Reidy-Lagunes D, Anthony LB et al (2013) Consensus guidelines for the management and treatment of neuroendocrine tumors. Pancreas 42:557–577. https://doi.org/10.1097/MPA.0b013e31828e34a4CrossRefPubMedPubMedCentral

Pavel M, Öberg K, Falconi M et al (2020) Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31:844–860. https://doi.org/10.1016/j.annonc.2020.03.304CrossRefPubMed

Shah MH, Goldner WS, Benson AB et al (2021) Neuroendocrine and adrenal tumors, version 2.2021. JNCCN J Natl Compr Cancer Netw 19:839–867. https://doi.org/10.6004/jnccn.2021.0032CrossRef

Yamaguchi T, Machida N, Morizane C et al (2014) Multicenter retrospective analysis of systemic chemotherapy for advanced neuroendocrine carcinoma of the digestive system. Cancer Sci 105:1176–1181. https://doi.org/10.1111/cas.12473CrossRefPubMedPubMedCentral

Morizane C, Machida N, Honma Y et al (2022) Effectiveness of etoposide and cisplatin vs irinotecan and cisplatin therapy for patients with advanced neuroendocrine carcinoma of the digestive system: The TOPIC-NEC phase 3 randomized clinical trial. JAMA Oncol 8:1447–1455. https://doi.org/10.1001/jamaoncol.2022.3395CrossRefPubMedPubMedCentral

Sorbye H, Grande E, Pavel M et al (2023) European Neuroendocrine Tumor Society ( ENETS ) 2023 guidance paper for digestive neuroendocrine carcinoma. J Neuroendocrinol. https://doi.org/10.1111/jne.13249CrossRefPubMed

Ready NE, Ott PA, Hellmann MD et al (2020) Nivolumab monotherapy and nivolumab plus ipilimumab in recurrent small cell lung cancer: results from the CheckMate 032 Randomized Cohort. J Thorac Oncol 15:426–435. https://doi.org/10.1016/j.jtho.2019.10.004CrossRefPubMed

10.

Sindhu KK, Nehlsen AD, Lehrer EJ et al (2022) Oligoprogression of solid tumors on immune checkpoint inhibitors: the impact of local ablative radiation therapy. Biomedicines. https://doi.org/10.3390/biomedicines10102481CrossRefPubMedPubMedCentral

11.

Sawayama H, Komohara Y, Hirao H et al (2020) Nivolumab exerts therapeutic effects against metastatic lesions from early gastric adenocarcinoma with a small proportion of neuroendocrine carcinoma after gastrectomy: a case report. Clin J Gastroenterol 13:759–765. https://doi.org/10.1007/s12328-020-01159-8CrossRefPubMed

12.

Patel SP, Othus M, Chae YK et al (2020) A phase II basket trial of dual anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART SWOG 1609) in patients with nonpancreatic neuroendocrine tumors. Clin Cancer Res. https://doi.org/10.1158/1078-0432.ccr-19-3356CrossRefPubMedPubMedCentral

13.

Santini D, Zeppola T, Russano M et al (2021) PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort. J Transl Med 19:1–8. https://doi.org/10.1186/s12967-021-02937-9CrossRef

14.

Cristescu R, Mogg R, Ayers M et al (2018) Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science. https://doi.org/10.1126/science.aar3593CrossRefPubMedPubMedCentral

15.

Le DT, Uram JN, Wang H et al (2015) PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med 372:2509–2520. https://doi.org/10.1056/nejmoa1500596CrossRefPubMedPubMedCentral

16.

McGranahan N, Furness AJS, Rosenthal R et al (2016) Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science 351:1463–1469. https://doi.org/10.1126/science.aaf1490CrossRefPubMedPubMedCentral

17.

Ogata T, Satake H, Ogata M et al (2018) Neutrophil-to-lymphocyte ratio as a predictive or prognostic factor for gastric cancer treated with nivolumab: a multicenter retrospective study. Oncotarget 9:34520–34527. https://doi.org/10.18632/oncotarget.26145

18.

Suzuki H, Yamada T, Sugaya A et al (2020) Retrospective analysis for the efficacy and safety of nivolumab in advanced gastric cancer patients according to ascites burden. Int J Clin Oncol. https://doi.org/10.1007/s10147-020-01810-xCrossRefPubMedPubMedCentral

19.

Xing J, Ying H, Li J et al (2020) Immune checkpoint markers in neuroendocrine carcinoma of the digestive system. Front Oncol 10:1–7. https://doi.org/10.3389/fonc.2020.00132CrossRef

20.

Lagos GG, Izar B, Rizvi NA (2020) Beyond tumor PD-L1: emerging genomic biomarkers for checkpoint inhibitor immunotherapy. Am Soc Clin Oncol Educ B 40:1–11. https://doi.org/10.1200/EDBK_289967CrossRef

21.

Patel SP, Kurzrock R (2015) PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 14:847–856. https://doi.org/10.1158/1535-7163.MCT-14-0983CrossRefPubMed

22.

Vijayvergia N, Dasari A, Deng M et al (2020) Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials. Br J Cancer 122:1309–1314. https://doi.org/10.1038/s41416-020-0775-0CrossRefPubMedPubMedCentral

23.

McLaughlin M, Patin EC, Pedersen M et al (2020) Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nat Rev Cancer 20:203–217. https://doi.org/10.1038/s41568-020-0246-1CrossRefPubMed

24.

Klemen ND, Wang M, Feingold PL et al (2019) Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. J Immunother cancer 7:196. https://doi.org/10.1186/s40425-019-0672-3CrossRefPubMedPubMedCentral

25.

Xu Y, Li H, Fan Y (2021) Progression patterns, treatment, and prognosis beyond resistance of responders to immunotherapy in advanced non-small cell lung cancer. Front Oncol 11:1–10. https://doi.org/10.3389/fonc.2021.642883CrossRef

26.

Schoenfeld JD, Giobbie-Hurder A, Ranasinghe S et al (2022) Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol 23:279–291. https://doi.org/10.1016/S1470-2045(21)00658-6CrossRefPubMedPubMedCentral

27.

Kawasaki E, Maruyama T, Imagawa A et al (2014) Diagnostic criteria for acute-onset type 1 diabetes mellitus (2012): report of the committee of Japan diabetes society on the research of fulminant and acute-onset type 1 diabetes mellitus. J Diabetes Investig 5:115–118. https://doi.org/10.1111/jdi.12119CrossRefPubMed

28.

Yamamoto N, Tsurutani Y, Katsuragawa S et al (2019) A patient with nivolumab-related fulminant type 1 diabetes mellitus whose serum C-peptide level was preserved at the initial detection of hyperglycemia. Intern Med 58:2825–2830. https://doi.org/10.2169/internalmedicine.2780-19CrossRefPubMedPubMedCentral

29.

Baden MY, Imagawa A, Abiru N et al (2019) Characteristics and clinical course of type 1 diabetes mellitus related to anti-programmed cell death-1 therapy. Diabetol Int 10:58–66. https://doi.org/10.1007/s13340-018-0362-2CrossRefPubMed

30.

Hughes J, Vudattu N, Sznol M et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55–e57. https://doi.org/10.2337/dc14-2349CrossRefPubMedPubMedCentral

Titel: Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis
verfasst von: Yusuke Seyama
Takeshi Yamada
Hirosumi Suzuki
Satoshi Fukuda
Miki Tsuji
Yusuke Niisato
Suguru Hirose
Yoshiyuki Yamamoto
Toshikazu Moriwaki
Ichinosuke Hyodo
Publikationsdatum: 12.05.2023
Verlag: Springer Nature Singapore
Erschienen in: International Cancer Conference Journal / Ausgabe 4/2023
Elektronische ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-023-00611-z

Springer Medizin

Gastric neuroendocrine carcinoma presenting complete durable response by nivolumab treatment for multiple metastases and radiotherapy to oligoprogressive metastasis

Abstract

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

A case of testicular seminoma with testicular abscess caused by Salmonella saintpaul

Myxoid liposarcoma in an 11-year-old patient

Successful multidisciplinary treatment with complete response to atezolizumab plus bevacizumab in a 90-year-old patient with hepatocellular carcinoma recurrence

Intrahepatic cholangiocarcinoma with FGFR2 fusion gene positive that responded to pemigatinib and caused hypophosphatemia

A rare case of pseudomyxoma peritonei with Morgagni hernia

Lethal ventricular arrhythmia due to entrectinib-induced Brugada syndrome: a case report and literature review

Neu im Fachgebiet Onkologie

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

Viel pflanzliche Nahrung, seltener Prostata-Ca.-Progression

Alter verschlechtert Prognose bei Endometriumkarzinom

Darf man die Behandlung eines Neonazis ablehnen?

Update Onkologie